FUTURE Trials Lead to Novel Treatment for Psoriatic Arthritis
Results from the FUTURE trials demonstrate significant reduction in disease burden and severity of PsA with secukinumab.
Results from the FUTURE trials demonstrate significant reduction in disease burden and severity of PsA with secukinumab.
Nearly half of all fractures in women over age 50 are associated with osteoporosis.
Which agent—DMARD or biologic—or combination is best for a patient with rheumatoid arthritis?